- Conditions
- Methamphetamine Dependence
- Interventions
- Atomoxetine, placebo
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 128
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Schizophrenia, Cognition, Smoking
- Interventions
- Atomoxetine (Strattera™)
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Obstructive Sleep Apnea, Hypertension
- Interventions
- AD113, Atomoxetine
- Drug
- Lead sponsor
- Apnimed
- Industry
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Towson, Maryland • Cincinnati, Ohio • Columbia, South Carolina
- Conditions
- Cocaine Dependence, Nicotine Dependence
- Interventions
- Progesterone, Placebo
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Depressive Symptoms
- Interventions
- Atomoxetine Hydrochloride, Sertraline, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Atomoxetine
- Drug
- Lead sponsor
- Monarch Medical Research
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Obstructive Sleep Apnea, Down Syndrome
- Interventions
- Atomoxetine and Oxybutynin (ato-oxy)
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Neurogenic Orthostatic Hypotension
- Interventions
- Atomoxetine, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 2
- States / cities
- New York, New York • Nashville, Tennessee
- Conditions
- Autonomic Failure, Orthostatic Hypotension
- Interventions
- Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
- Drug · Other · Dietary Supplement + 1 more
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 389 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2017
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- Atomoxetine, Methylphenidate
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • New York, New York
- Conditions
- Attention-Deficit/Hyperactivity Disorder (ADHD), Insomnia
- Interventions
- atomoxetine
- Drug
- Lead sponsor
- Rhode Island Hospital
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Cancer, Cognitive Late Effects
- Interventions
- Atomoxetine
- Drug
- Lead sponsor
- Temple University
- Other
- Eligibility
- 6 Years to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Attention Deficit Hyperactivity Disorder, Insomnia
- Interventions
- atomoxetine, placebo
- Drug
- Lead sponsor
- Rhode Island Hospital
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Attention Deficit Hyperactivity Disorder, ADHD
- Interventions
- fMRI scans, Atomoxetine arm, Methylphenidate arm
- Other · Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Placebo, Acetazolamide, Trazodone, Atomoxetine and eszopiclone
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Huntington Disease, Chorea
- Interventions
- atomoxetine, Matching Placebo
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Sleep Apnea
- Interventions
- Atomoxetine, Oxybutynin, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- ADHD NOS
- Interventions
- atomoxetine (Strattera)
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Placebo oral capsule, Atomoxetine Oral Capsule [Strattera]
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Memory Disorders, Multiple Sclerosis
- Interventions
- Atomoxetine, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Dosing 1: Atomoxetine, AD313
- Drug
- Lead sponsor
- Apnimed
- Industry
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Los Angeles, California • St Louis, Missouri
- Conditions
- ADHD, Attention Deficit Hyperactivity Disorder
- Interventions
- Methylphenidate, Atomoxetine
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 7 Years to 12 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Atomoxetine Hydrochloride
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Years to 16 Years
- Enrollment
- 377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Obstructive Sleep Apnea, Sleep-disordered Breathing
- Interventions
- Combination device and drug: Unilateral hypoglossal nerve stimulation & atomoxetine-plus-oxybutynin (HGNS+AtoOxy), Unilateral hypoglossal nerve stimulation (HGNS), active comparator condition, Atomoxetine-plus-oxybutynin (80/5 mg) (AtoOxy), active comparator condition, Placebo; placebo comparator condition
- Other · Device · Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts